Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Safusidenib [inn]
2. Rck8kk7sb9
3. (2e)-3-(1-{[5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)-1,2-oxazol-4-yl]carbonyl}-3-methyl-1h-indol-4-yl)prop-2-enoic Acid
4. (e)-3-(1-(5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)isoxazole-4-carbonyl)-3-methyl-1h-indol-4-yl)acrylic Acid
5. 1898206-17-1
6. 2-propenoic Acid, 3-(1-((5-(1-fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl)carbonyl)-3-methyl-1h-indol-4-yl)-, (2e)-
7. 2-propenoic Acid, 3-[1-[[5-(1-fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1h-indol-4-yl]-, (2e)-
8. Ab-291 Free Acid
9. Ds-1001 Free Acid
10. Unii-rck8kk7sb9
11. Chembl4651002
12. Schembl19216573
13. Gtpl11884
14. Bdbm278559
15. Bdbm278589
16. Ds-1001a
17. Us10040791, Example 21
18. Us10040791, Example 51
19. Hy-145594
20. Cs-0376579
21. (2e)-3-(1-{[5-(1,1- Difluoroethyl)-3-(2,4,6- Trichlorophenyl)-1,2-oxazol-4- Yl]carbonyl}-3-methyl-1h- Indol-4-yl)prop-2-enoic Acid
22. (2e)-3-[1-[[5-(1-fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1h-indol-4-yl]-2-propenoic Acid
23. (e)-3-(1-(5-(1-fluoro-1-methyl-ethyl)-3-(2,4,6-trichlorophenyl)isoxazole-4-carbonyl)-3-methyl-indol-4-yl)prop-2-enoic Acid
24. (e)-3-[1-[5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)-1,2-oxazole-4-carbonyl]-3-methylindol-4-yl]prop-2-enoic Acid
25. 7su
| Molecular Weight | 535.8 g/mol |
|---|---|
| Molecular Formula | C25H18Cl3FN2O4 |
| XLogP3 | 6.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 85.3 |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 834 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Safusidenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Safusidenib, including repackagers and relabelers. The FDA regulates Safusidenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Safusidenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Safusidenib supplier is an individual or a company that provides Safusidenib active pharmaceutical ingredient (API) or Safusidenib finished formulations upon request. The Safusidenib suppliers may include Safusidenib API manufacturers, exporters, distributors and traders.
Safusidenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Safusidenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Safusidenib GMP manufacturer or Safusidenib GMP API supplier for your needs.
A Safusidenib CoA (Certificate of Analysis) is a formal document that attests to Safusidenib's compliance with Safusidenib specifications and serves as a tool for batch-level quality control.
Safusidenib CoA mostly includes findings from lab analyses of a specific batch. For each Safusidenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Safusidenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Safusidenib EP), Safusidenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Safusidenib USP).
LOOKING FOR A SUPPLIER?
